Fatty liver disease affects approximately one in three UK adults, with growing interest in the role of gut health in liver function. Probiotics—live beneficial bacteria—have been investigated for their potential to support liver health through the gut-liver axis, though evidence remains modest and inconsistent. Whilst some research suggests certain probiotic strains may influence liver enzymes and metabolic pathways, they are not currently a standard treatment for fatty liver disease. This article examines the evidence for probiotics in fatty liver management, discusses specific strains studied in clinical research, and explains how to choose quality supplements safely whilst prioritising evidence-based lifestyle interventions recommended by NICE and NHS guidance.
Summary: No probiotic is currently licensed or recommended as standard treatment for fatty liver disease, though some Lactobacillus and Bifidobacterium strains show modest, inconsistent effects on liver enzymes in research.
- Probiotics may influence liver health through the gut-liver axis by modulating intestinal barrier function, bacterial metabolites, and inflammatory pathways.
- Most studied strains include Lactobacillus rhamnosus, Bifidobacterium longum, and multi-strain formulations, typically at 10–100 billion CFUs daily.
- Evidence shows small, inconsistent reductions in liver enzymes (ALT, AST) with no proven benefit on liver histology or fibrosis progression.
- Probiotics are generally safe but should be avoided by immunocompromised individuals, those with central lines, or critically ill patients.
- NICE guidance prioritises 5–10% weight loss, dietary changes, increased physical activity, and metabolic control as cornerstone NAFLD treatments.
- Probiotics are not available on NHS prescription for fatty liver and should complement, not replace, evidence-based medical management.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
Understanding Fatty Liver Disease and Gut Health
Fatty liver disease, medically termed hepatic steatosis, occurs when excess fat accumulates in liver cells. Non-alcoholic fatty liver disease (NAFLD) affects approximately one in three adults in the UK and represents a spectrum from simple steatosis to non-alcoholic steatohepatitis (NASH), which involves inflammation and potential progression to cirrhosis. The condition is strongly associated with obesity, type 2 diabetes, and metabolic syndrome. (You may also encounter the newer term metabolic dysfunction-associated steatotic liver disease, or MASLD, though NAFLD remains in current UK guidance.)
Emerging research has identified a relationship between gut health and liver function, often referred to as the 'gut-liver axis'. The liver receives approximately 70% of its blood supply from the intestinal circulation via the portal vein, meaning it is continuously exposed to gut-derived substances including bacterial products, nutrients, and metabolites. When the intestinal barrier becomes compromised—a condition known as increased intestinal permeability—bacterial components such as lipopolysaccharides may translocate to the liver. However, it is important to note that whilst associations between altered gut microbiota and NAFLD have been observed in research, causality and the clinical implications of these findings remain under investigation.
The gut microbiome, comprising trillions of microorganisms residing in the digestive tract, plays a role in metabolic health. Studies have demonstrated that individuals with NAFLD often exhibit altered gut microbiota composition (dysbiosis) compared to healthy individuals, with reduced microbial diversity and changes in specific bacterial populations. This dysbiosis may influence liver health through multiple mechanisms, including altered bile acid metabolism, increased production of ethanol by gut bacteria, and changes in short-chain fatty acid production, though the precise clinical significance of these changes is still being established.
Key factors linking gut health to fatty liver include:
-
Intestinal barrier integrity and permeability
-
Bacterial metabolite production affecting metabolism
-
Immune system activation via gut-derived signals
-
Bile acid signalling pathways between gut and liver
Proper assessment and risk stratification of NAFLD are essential. NICE guidance (NG49) recommends using non-invasive tests such as the FIB-4 score to identify individuals at risk of advanced fibrosis, with age-adjusted thresholds and further testing (such as the Enhanced Liver Fibrosis or ELF test) to guide referral to specialist hepatology services when indicated.
How Probiotics May Support Liver Health
Probiotics are defined by the World Health Organization as 'live microorganisms which, when administered in adequate amounts, confer a health benefit on the host'. These beneficial bacteria, primarily from Lactobacillus and Bifidobacterium genera, have been investigated for potential effects on liver health through several interconnected mechanisms. However, it is essential to emphasise that probiotics are not currently a standard treatment for fatty liver disease, and research in this area is ongoing with modest and inconsistent findings.
One proposed mechanism involves restoration of intestinal barrier function. Certain probiotic strains may strengthen tight junctions between intestinal cells, potentially reducing the translocation of harmful bacterial products to the liver. By maintaining barrier integrity, probiotics could theoretically decrease inflammatory signals reaching hepatic tissue. Additionally, probiotics may modulate the overall composition of the gut microbiome, promoting beneficial bacterial populations whilst reducing potentially harmful species. These mechanisms are largely based on preclinical and short-term human studies, and their clinical relevance to liver disease outcomes remains uncertain.
Probiotics may also influence metabolic pathways relevant to liver health. Some strains produce short-chain fatty acids (SCFAs) such as butyrate, propionate, and acetate through fermentation of dietary fibres. These metabolites have been shown to influence glucose and lipid metabolism, insulin sensitivity, and inflammatory responses—all factors relevant to NAFLD pathogenesis. Furthermore, certain probiotics can modify bile acid metabolism, which plays a role in lipid absorption and metabolic signalling.
Potential mechanisms of probiotic action include:
-
Reducing systemic inflammation and oxidative stress
-
Modulating immune responses
-
Possibly decreasing hepatic fat accumulation through metabolic effects
-
Small and inconsistent reductions in liver enzyme levels (ALT, AST) in some studies
-
Possible modest effects on insulin sensitivity
Importantly, whilst some studies have reported small reductions in liver enzymes, these changes are heterogeneous across trials and of uncertain clinical significance. There is no proven benefit of probiotics on liver histology, fibrosis progression, or long-term clinical outcomes in NAFLD. Probiotics should be viewed as a potential complementary approach only, not as a primary treatment.
Lifestyle modifications including weight loss of 5–10% of body weight, dietary changes (particularly reducing refined carbohydrates and saturated fats), increased physical activity, optimising control of diabetes and lipid disorders, and avoiding excessive alcohol remain the cornerstone of NAFLD management according to NICE guidance (NG49) and NHS recommendations. Probiotics should never replace or delay these evidence-based interventions.
Evidence-Based Probiotic Strains for Fatty Liver
Clinical research has investigated various probiotic strains for their potential effects on fatty liver disease, though the evidence base remains limited and further large-scale trials are needed. Most studies have been relatively small and of short duration, meaning results should be interpreted cautiously. Neither NICE nor the MHRA recommend or license any probiotic as standard treatment for NAFLD.
Lactobacillus and Bifidobacterium combinations have been most extensively studied. Several randomised controlled trials have examined multi-strain formulations containing species such as Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus rhamnosus, Bifidobacterium breve, and Bifidobacterium longum. Some studies reported modest reductions in liver enzyme levels (alanine aminotransferase and aspartate aminotransferase), though results have been inconsistent across trials and the clinical significance of these changes remains uncertain.
Systematic reviews and meta-analyses, including Cochrane Reviews, have examined probiotics in NAFLD. Whilst some suggest small improvements in liver enzymes and metabolic parameters, the quality of evidence is rated as low to moderate due to heterogeneity in study designs, probiotic formulations, dosages, and duration of treatment. Crucially, there is no proven benefit on liver histology, fibrosis progression, or long-term clinical outcomes.
Specific strains with some research support include:
-
Lactobacillus rhamnosus GG – studied for metabolic effects
-
Bifidobacterium longum – investigated in combination formulations
-
Lactobacillus casei – examined in several NAFLD trials
-
High-potency multi-strain probiotic formulations – studied in liver disease research (note that specific researched formulations may differ from products sold in the UK)
It is essential to recognise that probiotic effects are strain-specific and product-specific, meaning results from one strain or formulation cannot be extrapolated to others, even within the same species. Additionally, most research has been conducted in adults with NAFLD, and evidence in other populations is limited. Patients considering probiotics should discuss this with their healthcare provider as part of a comprehensive management plan that prioritises evidence-based lifestyle and medical interventions.
Choosing Probiotics: What to Look For
Selecting an appropriate probiotic supplement requires careful consideration, as the UK market contains numerous products with varying quality, formulations, and evidence bases. Unlike medicines, food supplements including probiotics are not subject to the same rigorous regulatory approval process by the MHRA. In the UK, food supplements fall under the oversight of the Food Standards Agency and Trading Standards, and disease risk reduction or treatment claims are restricted under ASA and CAP Code guidance. Quality and efficacy can vary considerably between products.
Key factors to consider when selecting a probiotic:
-
Strain identification: Look for products that clearly identify bacterial strains with full nomenclature (genus, species, and strain designation). Generic labels such as 'probiotic blend' without specific strain information provide limited assurance of efficacy.
-
Colony-forming units (CFUs): This indicates the number of viable bacteria per dose. Research in NAFLD has used formulations with widely varying doses, typically between 10 billion and 100 billion CFUs daily, though there is no established optimal dose and higher CFU counts do not necessarily equate to greater benefit. The evidence is too heterogeneous to recommend a specific CFU range with confidence.
-
Evidence base: Whilst no probiotic is specifically licensed for fatty liver disease, products containing strains that have been studied in clinical research may be preferable. However, the specific formulation and dose used in research may differ from commercial products available in the UK.
-
Storage requirements: Some probiotics require refrigeration to maintain viability, whilst others are shelf-stable. Follow storage instructions carefully to ensure bacterial survival.
-
Quality assurance: Choose products from reputable manufacturers that conduct third-party testing and provide information about manufacturing standards. Look for products manufactured to Good Manufacturing Practice (GMP) standards. Check that the product guarantees viable counts through the end of shelf life (not just at manufacture) and lists potential allergens and excipients.
-
Expiry dates: Probiotic viability decreases over time. Check expiry dates and purchase products with adequate shelf life remaining.
It is worth noting that probiotics are not regulated as medicines in the UK for most indications. The MHRA does not evaluate or approve food supplements for efficacy. Claims made by manufacturers should be viewed critically, and promotional language suggesting probiotics can 'treat' or 'cure' fatty liver disease should be treated with scepticism.
Patients should be aware that probiotic supplements represent an additional cost, typically ranging from £10 to £40 monthly, and are not available on NHS prescription for NAFLD. Given the modest and inconsistent evidence, probiotics should not replace established management strategies including dietary modification, weight loss of 5–10% of body weight, increased physical activity, and treatment of associated metabolic conditions such as type 2 diabetes and dyslipidaemia.
Safety Considerations and When to Seek Medical Advice
Probiotics are generally considered safe for most healthy individuals, with a well-established safety profile based on decades of use. Common probiotic strains such as Lactobacillus and Bifidobacterium species are part of the normal human microbiome and are consumed regularly in fermented foods like yoghurt and kefir. However, certain populations should exercise caution, and probiotics are not appropriate for everyone.
Potential adverse effects, when they occur, are typically mild and transient. These may include:
-
Digestive symptoms such as bloating, gas, or mild abdominal discomfort, particularly during the first few days of use
-
Changes in bowel habits
-
Rarely, allergic reactions in individuals sensitive to ingredients in the formulation
Serious adverse events are uncommon but have been reported in vulnerable populations. Individuals who should avoid probiotics or use them only under medical supervision include:
-
Those with severely compromised immune systems (e.g., undergoing chemotherapy, HIV/AIDS with low CD4 counts, organ transplant recipients)
-
Patients with central venous catheters or other indwelling medical devices
-
Individuals with inflammatory bowel disease during acute flares or other conditions affecting gut barrier integrity (discuss with your specialist on a case-by-case basis)
-
Those with short bowel syndrome or other structural gastrointestinal abnormalities
-
Critically ill patients in intensive care settings
In these populations, there have been rare reports of probiotic bacteraemia or fungaemia (bloodstream infections), though such cases remain exceptional.
Pregnancy and breastfeeding: Most common probiotic strains appear to be safe during pregnancy and breastfeeding, but evidence is limited. If you are pregnant, planning pregnancy, or breastfeeding, discuss probiotic use with your midwife or GP before starting.
Reporting side effects: If you experience a suspected side effect from a probiotic or any other medicine or supplement, you can report it via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk.
When to seek medical advice:
Patients should consult their GP or hepatologist before starting probiotics if they have been diagnosed with fatty liver disease, particularly if they have:
-
Advanced liver disease or cirrhosis
-
Other significant medical conditions or take multiple medications
-
Concerns about potential drug-supplement interactions
It is crucial to seek urgent medical attention if experiencing:
-
Severe abdominal pain
-
Jaundice (yellowing of skin or eyes)
-
Persistent vomiting
-
Signs of infection such as fever
-
Confusion or altered mental state (a potential sign of hepatic encephalopathy in advanced liver disease)
Patients should remember that fatty liver disease requires proper medical assessment and monitoring. Diagnosis typically involves blood tests (liver function tests, metabolic screening), imaging (ultrasound, FibroScan, or MRI), and sometimes liver biopsy. NICE guidance (NG49) recommends risk stratification using non-invasive tests such as the FIB-4 score as a first-line assessment. Age-adjusted thresholds are used (for example, FIB-4 <1.3 suggests low risk of advanced fibrosis; >2.67 suggests higher risk; in those over 65, a lower cut-off of >2.0 may be considered). Where indicated, further testing such as the Enhanced Liver Fibrosis (ELF) test is used to identify advanced fibrosis and guide referral to specialist hepatology services.
NICE and NHS guidance emphasise that management should focus on treating underlying causes, particularly weight reduction of 5–10% in overweight individuals, optimising control of diabetes and lipid disorders, increasing physical activity, and avoiding hepatotoxic substances including excessive alcohol. Probiotics should never replace medical evaluation or evidence-based treatments. Individuals concerned about liver health should contact their GP for appropriate investigation and a comprehensive management plan tailored to their specific circumstances.
Frequently Asked Questions
Can probiotics actually help reverse fatty liver disease?
Probiotics are not proven to reverse fatty liver disease and are not a standard treatment recommended by NICE or NHS guidance. Some studies show modest, inconsistent reductions in liver enzymes, but there is no evidence of benefit on liver histology, fibrosis progression, or long-term clinical outcomes.
Which probiotic strains are best for fatty liver?
Lactobacillus rhamnosus, Bifidobacterium longum, Lactobacillus casei, and multi-strain formulations containing Lactobacillus and Bifidobacterium species have been most studied in fatty liver research. However, results are inconsistent and no specific strain is licensed or recommended as treatment for NAFLD in the UK.
How do probiotics work for liver health through the gut?
Probiotics may support liver health by strengthening the intestinal barrier, reducing harmful bacterial translocation to the liver, producing beneficial metabolites like short-chain fatty acids, and modulating inflammation. These mechanisms are based largely on preclinical studies, and their clinical relevance to liver disease outcomes remains uncertain.
Can I take probiotics alongside medication for diabetes or high cholesterol?
Probiotics are generally safe to take with diabetes or cholesterol medications, though you should discuss this with your GP or pharmacist first. Probiotics should complement, not replace, prescribed treatments and evidence-based lifestyle changes such as weight loss and dietary modification for fatty liver management.
How long does it take for probiotics to improve fatty liver?
Most research studies have used probiotics for 8–24 weeks, with some showing small changes in liver enzymes during this period. However, the clinical significance of these changes is uncertain, and there is no established timeframe for meaningful liver health improvements from probiotics alone.
Are probiotics available on NHS prescription for fatty liver disease?
No, probiotics are not available on NHS prescription for fatty liver disease as they are not a recommended or licensed treatment for NAFLD. They are sold as food supplements and typically cost £10–40 monthly, which patients would need to pay for privately.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
